Screening in GORD won’t cut cancer rates: experts

There is no convincing evidence that endoscopic screening of patients with symptomatic gastro-oesophageal reflux disease (GORD) reduces rates of oesophageal cancer, Australian experts say.

In a commentary published today in JAMA Internal Medicine, Professor Nick Talley of the University of Newcastle and Dr Kate Napthali of the John Hunter Hospital noted that most cases of Barrett’s Oesophagus are missed despite widespread endoscopic screening of GORD patients.

Up to 95% of cases of oesophageal adenocarcinoma occur in